The Spanish Competition Authority fines two national pharmaceutical producers of PET radiopharmaceuticals for €5.76 million (Advanced Accelerator Applications / Novartis)

The CNMC fines the two main pharmaceutical producers of PET radiopharmaceuticals in Spain for €5.76 million* Radiopharmaceuticals are used in nuclear medicine tests to detect and monitor diseases such as cancer.The companies formed a cartel that, for at least four years, allocated the contracts to supply radiopharmaceuticals.This behaviour affected public and private hospitals and increased the cost of the service provided to patients.The Commission is also fining two of their executives as directly responsible for the offence. The CNMC has issued fines totalling €5.76 million to the companies Advanced Accelerator Applications

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Spanish Competition Authority, The Spanish Competition Authority fines two national pharmaceutical producers of PET radiopharmaceuticals for €5.76 million (Advanced Accelerator Applications / Novartis), 9 February 2021, e-Competitions February 2021, Art. N° 99248

Visites 391

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues